| WARF: P01331US |  |
| Method of Correcting HERG Channel Dysfunction |
| INVENTORS | • | Craig January |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of shortening prolonged QT intervals in a patient with abnormal HERG channel protein trafficking.
OVERVIEW
The human eag-related gene (HERG) encodes a potassium channel that is expressed in the heart. Mutations in the HERG channel are a common cause of long QT syndrome (LQTS), a disorder associated with delayed cardiac repolarization, prolonged electrocardiographic QT intervals and the development of ventricular arrhythmias and sudden death. Defective protein trafficking of mutant HERG channels is a common cause of one form of LQTS.
THE INVENTION
A UW-Madison researcher has developed a method of shortening prolonged QT intervals in a patient with abnormal HERG channel protein trafficking. The patient is treated with an effective amount of fexofenadine, which corrects the trafficking defect so that the mutant channels express large amplitude HERG current. This shortens the prolonged QT interval, reducing the risk of cardiac arrhythmia.
APPLICATIONS
- Treating LQTS
KEY BENEFITS
- Rescues human LQTS mutations without blocking HERG channels
- Reduces risk of arrhythmias and sudden death
- Suitable for all ages, from infants to adults
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Cardiovascular
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
